CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study Durable responses after ibritumomab tiuxetan radioimmunotherapy for
2013
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
7
References
0
Citations
NaN
KQI